Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Polygonatum odoratum polysaccharide 1 (POP1) is a neutral polysaccharide isolated from the rhizome of *Polygonatum odoratum (Mill.) Druce*, a plant widely used in traditional Chinese medicine for its yin-nourishing and hypoglycemic properties. POP1 is primarily composed of glucose and mannose residues and is characterized by specific structural features, including β-fructofuranose residues and 1→6 glycosidic bonds, which are essential for its biological activity. Mechanistically, POP1 ameliorates hyperglycemia by activating the phosphatidylinositol 3-kinase (PI3K)/protein kinase B (Akt) signaling pathway. This activation leads to the downstream regulation of glycogen synthase kinase 3β (GSK3β) and Forkhead Box Protein O1 (FoxO1), resulting in enhanced hepatic glycogen synthesis and suppressed gluconeogenesis. Currently in preclinical development, POP1 is being investigated as a potential functional food or pharmaceutical supplement for the management of diabetes and hyperglycemia.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on polygonatum odoratum polysaccharide 1.